Boston, MA 08/14/2014 (wallstreetpr) –According to reports, a new type of sleeping-drug produced by Merck & Co., Inc. (NYSE:MRK) has got the approval from FDA. Belsomra is a sleeping drug which will be very useful for people who are suffering from insomnia.
Details about Belsomra:
According to reports, Belsomra is a new generation sleeping pill that blocks chemicals known as orexins. These chemicals control the sleep cycle and don’t let the sufferer sleep during nights. Although Merck & Co., Inc. (NYSE:MRK) is quite confident about the new drug, but the health science professionals are not 100% clear about the efficiency about it. The reason told by one of the health science professionals was fair enough to doubt the efficiency of the pill. He said, “We have tested it against dummy rather than other sleeping medications; therefore, we are not yet clear if it is better than the old drug or not.”
After several tests, Food and Drug Administration finally said yes. It approved the drug in four divergent doses for different insomnia degrees. According to a spokesperson of agency, “A person who took 20 milligrams (which is considered a high dose) of Belsomra felt tired and found it very difficult to drive the car next morning.”
FDA’s Response:
It can make you feel drowsy and tired, hence take proper consultation from your doctor before using it. If you have to drive early morning that needs your full concentration, then don’t take a high dose of Belsomra. Your doctor would be the best source to know the ideal dose of Belsomra for a peaceful sleep.
Last year, after receiving a lot of complaints, FDA asked people to take lower quantity of Lunesta, Ambien and other related drugs. Some of the problems that were reported by victims included tiredness, lack of concentration, drowsiness and memory loss. FDA doesn’t want to repeat the same old story; hence, it has asked the patients to take the recommendation from experts before inhaling Belsomra.
